This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
September 2023 saw a wave of new pharmaceuticalmanufacturing facility expansions and launches across Europe. Importantly, each site features advanced technologies to support development and manufacture of these therapeutics. Materials and financing costs are high and squeezing manufacturers and their customers alike.
billion and another 200 new jobs is planned for Eli Lilly and Company’s two new pharmaceuticalmanufacturing sites in Boone County, US. Eli Lilly’s investment here is the largest manufacturing investment at a single location in its history. Students will also be able to access a smart manufacturing lab.
Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. Since 2010, the UK has fallen from 4th to 98th place in overall trade balance in pharmaceuticals, due to fierce global competition, according to the MMIP. It’s not all bad news.
There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.
BioNTech’s Singapore affiliate BioNTech Pharmaceuticals Asia Pacific has signed an agreement with Novartis Singapore PharmaceuticalManufacturing to acquire a GMP-certified manufacturing site in the country. . It also has the potential for extension into the manufacturing of other drug classes such as cell therapies. .
NCIMB Ltd provides microbial identification services and curates The National Collection of Industrial, Food and Marine Bacteria – one of the culture collections that makes up the UK Biological Resource Centre Network.
WHO confirmed that the newly approved WLAs include: The European Medicines Regulatory Network (EMRN), which is made up of the European Commission (EC), the European Medicines Agency (EMA) and the medicines regulatory authorities of 30 countries.
To appreciate the scope of the challenge facing the pharmaceutical market, as well as patients across the globe, we must understand that there are two distinct threats – ‘counterfeit’ and ‘falsified’ medicines. These may be mislabelled or produced in fake packaging and, most dangerously, there is no regulation around their manufacture.
The introduction of rapid microbiological testing methods, such as biofluorescent particle counters for real time detection of microbial contamination, has had an important impact on cell and gene therapy manufacturing. This is the first step towards the use of IoT technologies to enhance the management and maintenance of our cleanrooms.
Three trade bodies representing vaccine creators and manufacturers are endorsing The Berlin Declaration framework , a proposal that outlines how the industry would reserve an allocation of real-time vaccine production for swift distribution to priority populations in lower-income countries in future pandemics.
From the manufacturer perspective, payer policies and legislation on combination therapy pricing are impacting global development, pricing, access, and commercialization strategies. As a result, manufacturers are increasingly opting to not launch their combination indications in certain markets. Certain markets (e.g.,
Manufacturing delays and capacity issues that continue to impact the pharmaceutical supply chain have led to medicine shortages around the globe; an issue that has been exacerbated further by geopolitical events, the energy crisis and rising inflation. Globalisation and supply chain complexity are a factor.
Enhancing Development and Manufacturing Operations through Environmentally Sustainable Means The pharmaceutical industry’s evolving nature impacts patient care due to ongoing drug shortages from weakened operations. This not only boosts sustainability but also enhances process efficiency, leading to lower manufacturing costs and risks.
This process is representative of common microbial fermentation in the pharmaceutical industry, according to the authors. However, microbial-based fermentation results in numerous different challenges for in-line spectroscopy-based PAT, Reid et al. highlighted.
Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology. It also has the potential to reduce the high carbon footprint associated with manufacturing.
Juno Pharmaceuticals Canada has purchased Omega Laboratories, a specialist injectable pharmaceuticalmanufacturer in Canada, for an undisclosed sum. The merged entity represents one of the biggest specialist generic injectable operations in Canada with local manufacturing facilities.
Many companies use artificial intelligence (AI) to enable pharmaceuticalmanufacturers to overcome barriers to medication adherence. The AI engine predicts and identifies patients who are at risk and optimises interventions for them by channel, messages and timing.
The pharmaceutical supply chain is a global and complex network that includes a wide range of stakeholders such as pharmaceuticalmanufacturers, wholesale distributors, and pharmacy benefit managers (PBM), to ensure efficient and timely delivery of medications to the patients.
Bob is a life sciences and technology marketing leader with more than 25 years of experience working directly for pharmaceuticalmanufacturers (Merck, AstraZeneca, and Shire) and for technology companies that serve the industry (Appature, IQVIA, and Sparta). The post Bob Harrell appeared first on Pharma Marketing Network.
You’ll find areas that are biotech hotbeds, those that have numerous pharmaceuticalmanufacturers and so on. All you need to do is take the next steps, which involve enhancing your sales skills, learning more about medical sales and networking with people who work at companies nearby so you can get your foot in the door.
Calls have been made to allow lower-income countries to manufacture their own versions of vaccines or treatments, if they are unable to afford to buy the treatments. The industry has so far resisted demands for the sharing of intellectual property (IP) around products developed to counter the pandemic.
Driven by predictive analytics and machine learning, ACT ICS PRM allows manufacturers to rapidly identify patient behaviors and patterns to develop personas and predict the “next best action” for personalized engagement. Pharma Manufacturer Solutions. GM of Manufacturer Solutions. Aaron Crittenden. acrittenden@goodrx.com.
With the myriad of guidance and recommendations to boost diversity and inclusion in oncology trials, , biotech and pharmaceuticalmanufacturers are left to interpret the criteria and implement them through tangible action. J National Comprehensive Cancer Network. 2019;17(11):1309-1316. doi:10.6004/jnccn.2019.7321
Digital channels are defined as “ platforms for electronic communication through transmission of digital content over the internet or computer networks. It identifies the most used social media and digital channels and sets out specific guidance for each. Digital Channels include, but are not limited to, social media ”.
Take Charleston, South Carolina, for example, where a growing number of medical device and pharmaceuticalmanufacturers, research laboratories and service companies have sprung up or settled in recent years. In mid-sized Charleston, connections and collaborations are a constant.
Some want to attend live meetings (whether web-based, hybrid, or in person) to be able to network “face-to-face.” Despite the return of in-person meetings, pharmaceuticalmanufacturers and their stakeholders have experienced the benefits of virtual collaboration, and now realize that there is no going back.
Locating a subsidiary in close proximity to such an institution has advantages beyond pipeline talent, as there is the potential to access research and tap into networks for product development and clinical trials. Industry clusters. Locations with access to the sea may also offer a cheaper way of transporting goods.
The status isn’t awarded lightly and Chiesi is the largest pharmaceuticalmanufacturer to be named a B Corp. “We The non-profit B Labs issues B Corp certifications to businesses that can demonstrate a positive social and environmental impact, as well as make certain public commitments to accountability and transparency.
So I would expect we’re going to find the same type of welcoming environment, maybe even more so with the pharma marketing network brand behind us. If you’re a pharmaceutical company or if you’re an agency or even a consultant. 002 – John Mack Podcast Transcript appeared first on Pharma Marketing Network.
Google’s Policy Restrictions on Healthcare Advertising Google’s internal rules heavily restrict healthcare players like pharmaceuticalmanufacturers. For instance, pharmaceuticalmanufacturers can only promote prescription medicine ads in Canada, the US, and New Zealand – not anywhere else.
In the 1990s, generic pharmaceutical companies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. The energy-related slowdown in manufacturing will aggravate the ongoing drug shortages in Europe.”
In an age of disruption, technology is key to enabling pharmaceuticalmanufacturers monitor, track and control shipments and their processes. Pharmaceutical firms are changing the way they do business; the future winners will be highly automated and digitalised. But this results in huge, complex datasets.
The pharmaceutical industry relies on a globally integrated supply chain to source raw materials, active pharmaceutical ingredients (APIs), and finished medicines. Any disruption to this network can have significant consequences for drug availability, affordability, and research and development (R&D) investment.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content